方法：采用前瞻性临床对照的方法， 对60例POAG患者分别采用青光眼生活质量-15中文版(Glaucoma Quality of Life-15，GQL-15)和综合医院焦虑抑郁量表(Hospital Anxiety and Depression Scale， HADS)中文版评定患者最近1mo的生活质量和焦虑、抑郁状况，给予降压药物干预后1mo再次进行评定。60例健康自愿者作为对照，分析其心理和生活质量变化情况。

结果：POAG患者焦虑、抑郁及共患患者发生率分别为33.3%，26.7%，13.4%。患者抑郁焦虑评分及GQL评分与病程、眼压、年龄、药物种类和价格成正相关(P<0.05)，与平均月收入、视力成负相关(P<0.05)。通过降压药物干预，患者焦虑、抑郁评分及生活质量评分明显好转(F_焦虑评分=9.54， F_抑郁评分=6.88， F_GQL评分=8.82； P<0.05)。

结论：POAG患者焦虑、抑郁状况加重，生活质量明显降低。患者抑郁焦虑评分及生活质量评分与病程、年龄、平均月收入、药物种类、药物价格、视力、眼压、视野等方面紧密相关。降压药物干预有助于青光眼患者生活质量和心理逐步康复。

METHODS: Sixty POAG patients diagnosed in outpatient department in two hospitals from June 2009 to June 2011 were included. The personal data and case history were recorded and the patients underwent the glaucoma drug therapy. The life quality and anxiety and depression symptoms were evaluated by two instruments. Instruments applied included the Glaucoma Quality of Life-15(GQL-15)and Hospital Anxiety and Depression Scale(HADS).

RESULTS:The incidence of anxiety, depression, anxiety and depression in POAG was 33.3%,26.7%, 13.4%, respectively. Anxiety depression score and GQL-15 summary score was positively correlated with course, intraocular pressure, age, the species and price of drugs(P<0.05), and negatively correlated with income and vision(P<0.05). Compared with pre-therapy values, significant improvements were noted after hypotensive drug therapy in GQL-15 summary score, anxiety and depression scores(F_{anxiety scores} =9.54, F _{depression scores} =6.88, F_{GQL scores}=8.82; P<0.05).

CONCLUSION: There are lower life quality, higher positive anxiety and depression rates in POAG patients.The course, income, age and intraocular pressure, the species and price of drugs in POAG patients were affected in life quality, anxiety and depression and hypotensive drug interventions can improve life quality, anxiety and depression in POAG patients.